Narrative review shows that the short-term use of ketorolac is safe and effective in the management of moderate-to-severe pain in children

Pierluigi Marzuillo, Lorenzo Calligaris, Stefano Amoroso, Egidio Barbi

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

In June 2013, the European Medicine Agency recommended limiting codeine use in paediatric patients, creating a void in managing moderate pain. We reviewed the literature published in English (1985-June 2017) on the pharmacokinetic, pharmacodynamic and safety profile of ketorolac, a possible substitute for codeine and opioids, for treating moderate-to-severe pain. We found that gastrointestinal side effects were mainly reported with prolonged use, significant bleeding was reported in adenotonsillectomy, and adverse renal effects appeared to be limited to patients with specific coexisting risk factors.

CONCLUSION: The short-term use of ketorolac appears to be safe for children in many situations.

Original languageEnglish
JournalActa Paediatrica, International Journal of Paediatrics
DOIs
Publication statusE-pub ahead of print - Dec 16 2017

Fingerprint

Ketorolac
Codeine
Pain
Opioid Analgesics
Pharmacokinetics
Medicine
Pediatrics
Hemorrhage
Kidney
Safety

Cite this

@article{1ca8f1e86d144e699dcdcdd77f3891c2,
title = "Narrative review shows that the short-term use of ketorolac is safe and effective in the management of moderate-to-severe pain in children",
abstract = "In June 2013, the European Medicine Agency recommended limiting codeine use in paediatric patients, creating a void in managing moderate pain. We reviewed the literature published in English (1985-June 2017) on the pharmacokinetic, pharmacodynamic and safety profile of ketorolac, a possible substitute for codeine and opioids, for treating moderate-to-severe pain. We found that gastrointestinal side effects were mainly reported with prolonged use, significant bleeding was reported in adenotonsillectomy, and adverse renal effects appeared to be limited to patients with specific coexisting risk factors.CONCLUSION: The short-term use of ketorolac appears to be safe for children in many situations.",
author = "Pierluigi Marzuillo and Lorenzo Calligaris and Stefano Amoroso and Egidio Barbi",
note = "{\circledC}2017 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.",
year = "2017",
month = "12",
day = "16",
doi = "10.1111/apa.14189",
language = "English",
journal = "Acta Paediatrica, International Journal of Paediatrics",
issn = "0803-5253",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Narrative review shows that the short-term use of ketorolac is safe and effective in the management of moderate-to-severe pain in children

AU - Marzuillo, Pierluigi

AU - Calligaris, Lorenzo

AU - Amoroso, Stefano

AU - Barbi, Egidio

N1 - ©2017 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.

PY - 2017/12/16

Y1 - 2017/12/16

N2 - In June 2013, the European Medicine Agency recommended limiting codeine use in paediatric patients, creating a void in managing moderate pain. We reviewed the literature published in English (1985-June 2017) on the pharmacokinetic, pharmacodynamic and safety profile of ketorolac, a possible substitute for codeine and opioids, for treating moderate-to-severe pain. We found that gastrointestinal side effects were mainly reported with prolonged use, significant bleeding was reported in adenotonsillectomy, and adverse renal effects appeared to be limited to patients with specific coexisting risk factors.CONCLUSION: The short-term use of ketorolac appears to be safe for children in many situations.

AB - In June 2013, the European Medicine Agency recommended limiting codeine use in paediatric patients, creating a void in managing moderate pain. We reviewed the literature published in English (1985-June 2017) on the pharmacokinetic, pharmacodynamic and safety profile of ketorolac, a possible substitute for codeine and opioids, for treating moderate-to-severe pain. We found that gastrointestinal side effects were mainly reported with prolonged use, significant bleeding was reported in adenotonsillectomy, and adverse renal effects appeared to be limited to patients with specific coexisting risk factors.CONCLUSION: The short-term use of ketorolac appears to be safe for children in many situations.

U2 - 10.1111/apa.14189

DO - 10.1111/apa.14189

M3 - Review article

JO - Acta Paediatrica, International Journal of Paediatrics

JF - Acta Paediatrica, International Journal of Paediatrics

SN - 0803-5253

ER -